Latest news with #MedicalSector
Yahoo
29-07-2025
- Business
- Yahoo
Hims & Hers Health, Inc. (HIMS) Outperforms Broader Market: What You Need to Know
Hims & Hers Health, Inc. (HIMS) closed at $58.68 in the latest trading session, marking a +1.79% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%. The stock of company has risen by 16.68% in the past month, leading the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%. The investment community will be closely monitoring the performance of Hims & Hers Health, Inc. in its forthcoming earnings report. The company is scheduled to release its earnings on August 4, 2025. On that day, Hims & Hers Health, Inc. is projected to report earnings of $0.18 per share, which would represent year-over-year growth of 200%. At the same time, our most recent consensus estimate is projecting a revenue of $551.84 million, reflecting a 74.83% rise from the equivalent quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.75 per share and a revenue of $2.35 billion, signifying shifts of +177.78% and +58.88%, respectively, from the last year. Investors should also note any recent changes to analyst estimates for Hims & Hers Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.27% higher. Right now, Hims & Hers Health, Inc. possesses a Zacks Rank of #1 (Strong Buy). From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 77.22. This expresses a premium compared to the average Forward P/E of 27.59 of its industry. Also, we should mention that HIMS has a PEG ratio of 2.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical Info Systems industry stood at 3.15 at the close of the market yesterday. The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 74, finds itself in the top 30% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-07-2025
- Business
- Yahoo
Sensus Healthcare, Inc. (SRTS) Stock Drops Despite Market Gains: Important Facts to Note
Sensus Healthcare, Inc. (SRTS) closed at $5.51 in the latest trading session, marking a -2.48% move from the prior day. This move lagged the S&P 500's daily gain of 0.4%. At the same time, the Dow added 0.47%, and the tech-heavy Nasdaq gained 0.24%. Coming into today, shares of the company had gained 17.22% in the past month. In that same time, the Medical sector gained 1.19%, while the S&P 500 gained 4.61%. The upcoming earnings release of Sensus Healthcare, Inc. will be of great interest to investors. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $8.8 million, indicating a 4.76% downward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.11 per share and a revenue of $41.95 million, signifying shifts of -73.17% and +0.34%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Sensus Healthcare, Inc. presently features a Zacks Rank of #4 (Sell). Looking at valuation, Sensus Healthcare, Inc. is presently trading at a Forward P/E ratio of 51.36. For comparison, its industry has an average Forward P/E of 23.12, which means Sensus Healthcare, Inc. is trading at a premium to the group. The Medical - Instruments industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 165, finds itself in the bottom 34% echelons of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sensus Healthcare, Inc. (SRTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18-07-2025
- Business
- Yahoo
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.39% at $32.07. This move outpaced the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.52%, while the tech-heavy Nasdaq appreciated by 0.74%. Prior to today's trading, shares of the company had gained 20.36% outpaced the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is predicted to post an EPS of -$0.44, indicating a 120% decline compared to the equivalent quarter last year. For the full year, the Zacks Consensus Estimates project earnings of -$1.86 per share and a revenue of $25 million, demonstrating changes of -84.16% and 0%, respectively, from the preceding year. Any recent changes to analyst estimates for Viking Therapeutics, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Viking Therapeutics, Inc. boasts a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 83, this industry ranks in the top 34% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
16-07-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) ended the recent trading session at $52.73, demonstrating a -6.54% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.4%. At the same time, the Dow lost 0.98%, and the tech-heavy Nasdaq gained 0.18%. The stock of company has risen by 35.69% in the past month, leading the Medical sector's loss of 1.56% and the S&P 500's gain of 4.97%. The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$1.54, marking a 3.36% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $5.89 million, up 1032.88% from the year-ago period. CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$5.54 per share and revenue of $39.95 million. These results would represent year-over-year changes of -27.65% and +7.06%, respectively. It is also important to note the recent changes to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 77, finds itself in the top 32% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
11-07-2025
- Business
- Yahoo
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $31.29, demonstrating a +2.93% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.28% for the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq added 0.09%. The stock of company has risen by 5.01% in the past month, leading the Medical sector's gain of 0.24% and the S&P 500's gain of 4.37%. The upcoming earnings release of Viking Therapeutics, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.86 per share and revenue of $25 million, which would represent changes of -84.16% and 0%, respectively, from the prior year. It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 32% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
